Pictilisib

ArtNr	HY-50094-50mg
Hersteller	MedChem Express
CAS-Nr.	957054-30-7
Menge	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 50 mg
Kategorie	Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.80
Citations	[1]Wallin JJ, et al. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of RP-56976 in human breast cancer models by increasing cell death in vitro and in vivo.Clin Cancer Res. 2012 Jul 15;18(14):3901-11. Epub 2012 May 14.\|[2]Wullschleger S, et al. Quantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma.Anticancer Res. 2012 Feb;32(2):415-20.\|[3]Zou ZQ, et al. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.Mol Med Report. 2012 Feb;5(2):503-8.\|[4]Burrows N, et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.J Clin Endocrinol Metab. 2011 Dec;96(12):E1934-43. Epub 2011 Oct\|[5]Folkes AJ, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . J Med Chem. 2008 Sep 25;51(18):5522-32.\|[6]Ni J, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov. 2012 May;2(5):425-33.\|[7]Cheng H, et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res. 2014 Jan 1;74(1):15-23. Arab J Gastroenterol. 2025 Jan 4:S1687-1979(24)00132-1.\|Biochem J. 2022 Oct 14;479(19):2131-2151.\|Bioorg Med Chem Lett. 2012 Mar 1;22(5):1874-8. \|bioRxiv. 2020 Mar.\|Br J Cancer. 2021 Mar 15.\|Cancer Discov. 2012 May;2(5):425-33.\|Cancer Res. 2014 Jan 1;74(1):15-23.\|Cancer Res. 2024 Jun 17.\|Cancers. 2020 Jul 16;12(7):1918.\|Cell Biosci. 2022 Aug 21;12(1):135.\|Cell Cycle. 2019 Jul;18(13):1513-1522. \|Cell Metab. 2012 Mar 7;15(3):382-94.\|Cell Metab. 2021 Nov 2;33(11):2247-2259.e6.\|Cell Rep. 2023 May 29;42(6):112570.\|Cell Syst. 2020 Jan 22;10(1):66-81.e11.\|Cell. 2023 Jun 22;186(13):2929-2949.e20.\|Chem Biodivers. 2025 Mar 1:e202403291.\|Debreceni egyettemmolekularis orvostudomany. 2024 Dec.\|Harvard Medical School LINCS LIBRARY\|Int J Clin Exp Pathol. 2017;10(3):3033-3042.\|Int J Oncol. 2017 Sep;51(3):823-831.\|J Cell Biol. 2020 Dec 7;219(12):e202001031.\|J Clin Endocrinol Metab. 2021 Jan 1;106(1):e232-e246.\|J Clin Invest. 2022 Nov 22;e153470.\|J Pharm Anal. 2024 Aug 29.\|J Surg Res. 2022 Oct 20;282:137-146.\|Lipids Health Dis. 2024 Sep 4;23(1):282.\|MedComm (2020). 2024 Aug 12;5(8):e684.\|Molecules. 2019 Apr 1;24(7):1260.\|Molecules. 2020 Apr 23;25(8):1980.\|Nat Biomed Eng. 2018 Aug;2(8):578-588.\|Nat Cancer. 2024 Mar;5(3):433-447.\|Nat Chem Biol. 2017 Jan;13(1):38-45.\|Nat Chem Biol. 2024 Oct 31.\|Nat Commun. 2015 Oct 7;6:8501. \|Nat Commun. 2016 Feb 2;7:10438.\|Nature. 2018 Aug;560(7719):499-503.\|Oncogene. 2016 Jun 9;35(23):2961-70. \|Oncol Lett. 2023 Nov 15.\|Oncol Rep. 2023 May 9.\|Oncotarget. 2016 Aug 16;7(33):53515-53525.\|Oncotarget. 2016 May 31;7(22):32641-51. \|Patent. US20210236501A1.\|Patent. US20220313694A1.\|Research Square Preprint. 2024 Nov 26.\|Sci Rep. 2021 Jan 11;11(1):291.\|Sci Signal. 2021 Dec 21;14(714):eabj0057.\|Sci Transl Med. 2013 Jul 31;5(196):196ra99.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Tierärztliche Hochschule Hannover. 2021 Jul.\|Transl Oncol. January 2022, 101260.\|Cell Rep. 2020 Sep 29;32(13):108196.
Smiles	CS(N1CCN(CC2=CC3=C(C(N4CCOCC4)=NC(C5=CC=CC6=C5C=NN6)=N3)S2)CC1)(=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GDC-0941
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; PI3K
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	513.64
Product Description	Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Autophagy; PI3K/Akt/mTOR
Isoform	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ
Clinical information	Phase 2

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-50094-50mg-safety-datasheet.pdf